The FDA delayed a decision on allowing the so-called morning-after contraceptive pill to be sold without a prescription, according to the drug's producer, Barr Pharmaceuticals. The FDA last year rejected Barr's initial application to make the Plan B drug available for OTC use. Shortly after the delay was announced, the Center for Reproductive Rights filed suit in federal court claiming the FDA had failed to follow its own procedures or statutory or regulatory rules when it first rejected OTC status for the pill.

Full Story:

Related Summaries